Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer.

Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer. Int J Mol Sci (2017) 0.75

SensiScreen®KRAS exon 2-sensitive simplex and multiplex real-time PCR-based assays for detection of KRAS exon 2 mutations. PLoS One (2017) 0.75

Hallmarks of cancer: the next generation. Cell (2011) 140.01

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82

Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56

A genetic model for colorectal tumorigenesis. Cell (1990) 44.37

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 37.09

Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 31.48

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res (2006) 13.98

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene (2007) 11.85

First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med (2014) 10.91

Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med (2009) 10.01

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol (2007) 9.29

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature (2012) 8.77

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol (2011) 8.66

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol (2014) 8.48

Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol (2005) 8.15

Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med (2012) 7.47

Microsatellite instability in colorectal cancer. Gastroenterology (2010) 7.39

Molecular genetics of colorectal cancer. Annu Rev Pathol (2011) 7.24

Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2014) 6.95

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med (2012) 6.77

A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med (2013) 6.09

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst (2009) 4.42

The consensus molecular subtypes of colorectal cancer. Nat Med (2015) 4.35

Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol (2003) 3.70

PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol (2014) 3.61

BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res (2003) 3.39

Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol (2013) 3.34

The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov (2014) 3.32

Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol (2010) 3.30

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol (2010) 3.12

Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol (2010) 3.03

Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med (2013) 2.96

The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer (2008) 2.95

Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol (2009) 2.92

Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res (1995) 2.84

Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol (2012) 2.74

Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data. J Natl Cancer Inst (2014) 2.71

Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer (2011) 2.68

Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology (2008) 2.64

Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol (2011) 2.55

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res (2011) 2.22

A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer (2010) 1.91

MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res (2012) 1.87

Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut (2005) 1.87

Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J Clin Oncol (2011) 1.84

Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology (2014) 1.84

The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta (2008) 1.77

Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J Pathol (2013) 1.71

Frequency of loss of hMLH1 expression in colorectal carcinoma increases with advancing age. Cancer (2003) 1.62

Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer (2013) 1.60

Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res (2012) 1.51

HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin Cancer Res (2010) 1.50

Evaluating many treatments and biomarkers in oncology: a new design. J Clin Oncol (2013) 1.49

Characterization of the interactome of the human MutL homologues MLH1, PMS1, and PMS2. J Biol Chem (2006) 1.48

Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol (2013) 1.41

Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med Genomics (2012) 1.39

ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers. Mol Cancer Res (2013) 1.38

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC Cancer (2013) 1.32

Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol (2009) 1.29

MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor. J Biol Chem (2011) 1.13

Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas. Int J Cancer (2015) 1.03

Regulation of amphiregulin and epiregulin expression in human colonic subepithelial myofibroblasts. Int J Mol Med (2006) 1.02

Functions and Regulation of the PTEN Gene in Colorectal Cancer. Front Oncol (2014) 0.97

RAS mutations in colorectal cancer. N Engl J Med (2013) 0.96

ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. Cell Rep (2014) 0.92

Germline variants in POLE are associated with early onset mismatch repair deficient colorectal cancer. Eur J Hum Genet (2014) 0.89

Prognostic impact of microsatellite instability in colorectal cancer patients treated with adjuvant FOLFOX. Anticancer Res (2010) 0.83

Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy. Z Gastroenterol (2014) 0.80

Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan. Int J Oncol (2013) 0.80

The next generation of targeted therapy trials in colorectal cancer. Clin Adv Hematol Oncol (2014) 0.76